Indevus Rides High On Double Good News
This article was originally published in The Pink Sheet Daily
Executive Summary
No new trials for testosterone therapy, FDA says; separate Teva deal sweetens the pot.
You may also be interested in...
FDA Safety Concerns About Indevus’ Nebido Could Add 24 Months To Approval Timeline
Study to assess safety of hypogonadism therapy's oil-based depot injection could take 18 months.
Allergan Gains Sanctura XR Rights With Esprit Purchase
Indevus is in “a far stronger marketing position” for the overactive bladder product under a new license agreement with Allergan, Indevus CEO says.
No Pauses For Pagoclone: Indevus Moving To Phase III For Stuttering
The anxiolytic would be the first drug indicated for the condition.